BCM
ACRS icon

BML Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

BML Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.3M Sell
11,975,000
-2,275,000
-16% -$10.1M 35.98% 1
2026
Q1 		$53.4M Hold
14,250,000
– – 34.31% 1
2025
Q4 		$42.9M Hold
14,250,000
– – 37.08% 1
2025
Q3 		$27.1M Hold
14,250,000
– – 24.79% 1
2025
Q2 		$20.2M Hold
14,250,000
– – 15.31% 3
2025
Q1 		$21.8M Hold
14,250,000
– – 17.65% 2
2024
Q4 		$35.3M Hold
14,250,000
– – 21.95% 1
2024
Q3 		$16.4M Buy
14,250,000
+1,261,866
+10% +$1.55M 9.64% 4
2024
Q2 		$14.3M Buy
12,988,134
+3,592,200
+38% +$4.22M 10.2% 4
2024
Q1 		$11.7M Buy
9,395,934
+8,742,827
+1,339% +$10.4M 7.68% 5
2023
Q4 		$686K Buy
+653,107
New +$1.99M 0.52% 28

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BML Capital Management's ACRS Position: Q2 2026 in Review

BML Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 16% in Q2 2026, selling an estimated $10.1M and leaving 11,975,000 shares worth $63.3M. The position accounts for 35.98% of the portfolio, ranked #1.

BML Capital Management first reported a position in ACRS in Q4 2023 and has held it in 11 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • BML Capital Management held 11,975,000 shares of Aclaris Therapeutics worth $63.3M as of Q2 2026.
  • BML Capital Management sold 2,275,000 Aclaris Therapeutics shares in Q2 2026, an estimated $10.1M.
  • Aclaris Therapeutics made up 35.98% of BML Capital Management's portfolio in Q2 2026, its #1 holding.
  • BML Capital Management first reported a position in Aclaris Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.